Browse the evidence

Adherence to a Mediterranean diet (MedDiet) mitigates the increased risk of type 2 diabetes and metabolic dysfunction associated with the TCF7L2 rs7903146 T-allele, effectively neutralizing the genetic predisposition when adherence is high.

If you carry the TCF7L2 rs7903146 T-allele (a common genetic variant linked to higher diabetes risk), strict adherence to a Mediterranean-style diet is your most powerful tool. It doesn't just help; it specifically neutralizes the genetic disadvantage, keeping your weight, waist circumference, and diabetes risk in check. Focus on high adherence to this pattern rather than just isolated nutrients.

GLP-1 RA treatment is associated with significant lean tissue (muscle) loss, with studies showing 14-40% of total weight loss being lean mass, necessitating interventions to preserve muscle.

While GLP-1 RAs are effective for weight loss, they also cause muscle loss (14-40% of total weight loss). To protect your strength and metabolism, it is crucial to consume adequate protein and engage in resistance exercise during treatment. This is especially important for older adults or those already at risk of muscle loss.

Discontinuation of GLP-1 RA therapy is associated with significant weight regain, suggesting that these medications may need to be used as long-term maintenance treatments rather than short-term interventions.

Stopping GLP-1 RAs often leads to significant weight regain. If you are considering stopping, discuss a long-term maintenance plan with your doctor, which may include tapering the dose gradually or continuing a lower dose. This is especially important if you have limited access to the medication.

Adherence to digital GLP-1 RA-supported weight loss programs is significantly influenced by patient demographics, with older, Caucasian, and overweight individuals adhering significantly longer than younger, non-Caucasian, and higher BMI-class peers.

If you are using a digital GLP-1 program, be aware that adherence varies by demographic. Older, Caucasian, and overweight individuals in this study tended to stay in the program longer. However, the most common reasons for stopping are cost and side effects. To improve your chances of long-term success, proactively manage side effects with your care team and address financial concerns early, as these are the primary drivers of discontinuation.

In real-world digital weight loss programs combining behavioral therapy and GLP-1 receptor agonists (GLP-1 RAs), inadequate supply of the desired medication is the primary driver of patient discontinuation, outweighing cost and dissatisfaction with outcomes.

If you are using a digital weight loss program that includes GLP-1 medication, expect that medication supply issues are the most common reason for stopping treatment. To stay in the program, be prepared to discuss alternative medications with your care team if your preferred drug is unavailable, rather than discontinuing entirely. Also, consider the total value of the multidisciplinary support (doctors, dietitians, nurses) when evaluating the monthly cost, as cost is the second most common reason for dropping out.

Older pharmacotherapies (diethylpropion, orlistat, phentermine/topiramate) result in modest weight loss (3-7%) and are associated with significant side effects, making them less effective than newer GLP-1 agonists.

Older weight loss drugs like Orlistat (Xenical) can help you lose weight (average 15% in trials) but are less effective than newer GLP-1 injections. Orlistat works by blocking fat absorption. It must be taken with meals containing fat. Side effects like oily spotting are common if you eat too much fat. It is a second-line option.

Long-term participation in an intensive lifestyle intervention (ILI) for type 2 diabetes reduces reward-related neural reactivity to high-calorie food cues and enhances attention/visual processing compared to standard diabetes support.

If you have type 2 diabetes and are overweight, sticking to a structured lifestyle program (diet and exercise) for a long period can physically change how your brain reacts to high-calorie foods. Specifically, it may reduce the 'reward' signal and increase your brain's ability to pay attention to and process food cues consciously, which might support long-term weight management.

Online behavioral obesity treatment programs achieve higher implementation success in primary care when they are perceived as having high design quality, low cost, and strong compatibility with clinical workflows.

For primary care clinics adopting online weight loss tools, prioritize programs with clean, intuitive interfaces and zero cost to the provider. Ensure the tool fits seamlessly into existing workflows to avoid being deprioritized due to time constraints.

Trust in the intervention source (e.g., a local university) is a critical facilitator for clinician buy-in and patient enrollment in online obesity treatments.

When promoting online weight loss programs, explicitly highlight the affiliation with trusted local institutions (universities, hospitals) to overcome patient skepticism and clinician hesitation.

Clinician time savings and cost-effectiveness relative to commercial programs are key drivers for the successful implementation of online obesity treatments.

Emphasize to patients and providers that online programs are often free and do not require purchasing expensive specialty foods, making them more sustainable than commercial alternatives.

Hypoglossal nerve stimulation (HGNS) significantly reduces apnea-hypopnea index (AHI) and improves sleep quality in adults with moderate-to-severe OSA who are intolerant of or fail CPAP therapy.

If you have moderate-to-severe sleep apnea and cannot tolerate CPAP, ask your doctor about hypoglossal nerve stimulation (HGNS). It involves a small implant that stimulates the nerve controlling your tongue to keep your airway open during sleep. It is not for everyone (e.g., severe obesity or specific anatomical issues may exclude you), but for eligible patients, it significantly reduces apnea events and improves sleep quality without the daily hassle of a CPAP machine.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce AHI and body weight in patients with obesity and moderate-to-severe OSA, with tirzepatide showing superior efficacy compared to other GLP-1 RAs.

If you have obesity and moderate-to-severe sleep apnea, ask your doctor about GLP-1 receptor agonists like tirzepatide (Zepbound). These medications help with weight loss and have been shown to significantly reduce the severity of sleep apnea. They are taken as a weekly injection and can have gastrointestinal side effects, but these often improve over time. This treatment is particularly beneficial for those whose OSA is driven by obesity.

GLP-1 agonist medications (e.g., semaglutide 2.4 mg) produce clinically significant weight loss (approx. 12.4-12.5%) and improve multiple health markers independent of weight loss, but their use carries risks of medicalizing weight and increasing social stigma.

GLP-1 medications like semaglutide are highly effective for weight loss and improving health markers, but they are not without social costs. If you consider using them, be aware that you may face stigma from others who view it as an 'easy way out' or fear that it medicalizes your body. A patient-centered approach focuses on your overall health and well-being rather than just the number on the scale, and acknowledges these social realities.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) significantly reduce energy intake and hunger while improving satiety, but current clinical trials largely fail to report detailed dietary quality or food intake data, limiting the ability to tailor nutritional counseling.

GLP-1 medications like semaglutide and tirzepatide effectively reduce hunger and energy intake, leading to significant weight loss. However, because most clinical trials do not report detailed dietary quality, patients should proactively track their food intake and nutrient quality to ensure long-term success and prevent nutritional deficiencies, as the drug alone does not guarantee healthy eating habits.

Reduced gut microbial diversity (alpha-diversity) and specific taxonomic shifts (e.g., depletion of Akkermansia muciniphila and Faecalibacterium prausnitzii) are consistently associated with obesity and metabolic syndrome, serving as a marker of a less resilient microbiome.

Focus on dietary patterns that support microbial diversity (e.g., fiber-rich diets) rather than seeking simple diagnostic ratios. A diverse diet supports a resilient microbiome, which is associated with better metabolic health.

Short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate promote satiety and improve metabolic health by stimulating GLP-1 and PYY secretion and modulating gut-brain signaling, despite inconsistent fecal level measurements in obesity.

Consume fiber-rich foods to support SCFA production. This supports satiety hormones (GLP-1/PYY) and gut health, even if direct measurement of SCFAs is not feasible.

Elevated circulating branched-chain amino acids (BCAAs) and imidazole propionate (IMP) are causally linked to insulin resistance and type 2 diabetes, serving as predictive biomarkers years before clinical onset.

Monitor metabolic health through regular check-ups. Dietary patterns that improve insulin sensitivity (e.g., balanced macronutrients, fiber) can help manage BCAA and IMP levels.

Metabolic bariatric surgery (specifically malabsorptive procedures like Roux-en-Y gastric bypass) offers higher remission rates for Type 2 Diabetes than restrictive procedures (like sleeve gastrectomy), particularly in patients with severe obesity (BMI ≥ 35).

If you have severe obesity (BMI 35+) and Type 2 Diabetes, metabolic surgery (specifically bypass) is the most effective intervention for remission, offering double the success rate of sleeve gastrectomy. While invasive, it provides superior long-term glycemic control and lower relapse rates compared to other surgical options.

Incretin-based medications (GLP-1 RAs, dual/tri-agonists) achieve high rates of glycemic control (HbA1c ≤ 6.5%) and weight loss, but technically do not constitute 'remission' as defined by the consensus (which requires being off medication), as the effect persists only while taking the drug.

Newer incretin-based medications (like GLP-1 and dual/tri-agonists) are highly effective at lowering blood sugar and promoting weight loss, with some trials showing over 80% of patients reaching normal HbA1c levels. However, this control is dependent on continuing the medication and does not constitute 'remission' in the strict sense of being off all drugs.

Discontinuation of incretin agonists (GLP-1/GIP) leads to significant weight regain (approx. two-thirds of lost weight) within weeks, indicating that current pharmacological efficacy is not sustainable without continuous treatment.

Current GLP-1 and GIP medications are not a one-time fix for obesity. If you stop taking them, you will likely regain most of the weight you lost. This suggests that obesity management with these drugs is a long-term commitment, similar to other chronic conditions, and requires ongoing medical supervision and cost consideration.

Physical activity levels are significantly lower in obese patients with Type 2 Diabetes compared to non-obese patients, and this difference persists even when total energy intake is similar between groups.

Obese diabetic patients tend to be significantly less physically active than non-obese patients. Since calorie intake may not differ, increasing physical activity is a critical component of weight management.

Early weight loss (first 14 days) in a behavioral weight management program predicts long-term weight loss trajectory patterns, specifically differentiating those who achieve sustained loss from those who do not, although it does not distinguish between different types of successful sustained loss patterns.

If you are starting a weight loss program, do not judge your success or failure in the first two weeks. The data shows that how much you lose in the first 14 days does not predict *how* you will lose weight long-term (steady vs. plateau), but it does predict *if* you will lose weight significantly. If you are not losing weight early, do not quit. Instead, focus on adherence. If you are losing weight, do not expect that fast loss will continue linearly. The key to long-term success is staying in the program for the long haul, regardless of the initial speed.

Once-daily oral semaglutide (up to 14 mg) reduces systolic blood pressure and total cholesterol in patients with type 2 diabetes.

If you have Type 2 Diabetes, adding oral semaglutide to your current regimen can help lower your systolic blood pressure and total cholesterol. The standard protocol starts at a low dose (3 mg) and increases to 14 mg daily over two months to minimize side effects. This oral option offers cardiovascular protection similar to the injectable version, which may be easier for you to stick with long-term.

Oral semaglutide consistently reduces LDL cholesterol and triglycerides, but its effect on HDL cholesterol is inconsistent and clinically insignificant.

Oral semaglutide helps lower 'bad' cholesterol (LDL) and triglycerides in most patients with Type 2 Diabetes. However, do not expect it to reliably raise 'good' cholesterol (HDL), as studies show mixed and clinically insignificant results for HDL changes.